SINGULAIR (montelukast sodium) by Merck & Co. is leukotriene receptor antagonists [moa]. First approved in 2002.
Drug data last refreshed 1m ago · AI intelligence enriched 3h ago
SINGULAIR (montelukast sodium) is an oral leukotriene receptor antagonist approved in 2002 for asthma and allergic rhinitis. It works by blocking leukotrienes, inflammatory mediators that cause airway constriction and mucus production. The granule formulation enables pediatric dosing.
LOE-stage product with modest Part D volume signals a mature, cost-managed portfolio position with likely reduced team headcount and focus on retention strategies.
Leukotriene Receptor Antagonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers
Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects
A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)
Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)
Worked on SINGULAIR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on SINGULAIR during LOE offers limited growth trajectory but solid foundational experience in mature asset management, payer negotiation, and generic transition strategy. Roles emphasize cost optimization and market defense rather than expansion.